BioAscent Discovery Ltd on Using Compounds to Drive Collaboration
Download Your Copy
We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.
The pharmaceutical industry clearly understands there are issues associated with the R&D model that has existed for many years, and are actively investigating ways to dramatically improve the return on investment, thus making their company both profitable and sustainable.
Large pharmaceutical companies, such as AstraZeneca, Bayer, GSK, Lilly and Johnson and Johnson, are investing significant resource into Open Innovation, in order to harness the technical and scientific resources of research groups with the company. It is not just large pharma who can understand the advantages of these initiatives, however the need for dedicated resources required to facilitate collaborations, can act as a barrier to smaller organisations. Read more, download the full whitepaper here.
Have Your Say
Rate this feature and give us your feedback in the comments section below
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.